Michael Kyriakides

Michael is a Partner of Syncona Investment Management Ltd. Michael is a Director on the board of Purespring Therapeutics and an Observer to the board of Clade Therapeutics. He also supports Syncona portfolio company Freeline Therapeutics. Prior to joining Syncona, Michael worked in the life science practice of strategy consultancy L.E.K. Consulting in London, UK.

Michael received his Doctorate degree from the Department of Surgery and Cancer at Imperial College London. Michael also holds a Masters in Research in Biomedical Research, as well as a Bachelor of Science in Biochemistry.